InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,762.48
(
0.42%
)
US TECH 100
19,499.20
(
0.15%
)
Dow Jones
42,330.15
(
0.04%
)
Brent Oil
71.49
(
-0.69%
)
Bitcoin
64,016.28
(
1.08%
)
Post# of 253261
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Regulardoc

Send PM Follow Ignore
Followers 5
Posts 323
Boards Moderated 0
Alias Born 07/27/2010

Regulardoc

Re: exwannabe post# 128103

Sunday, 10/09/2011 8:14:28 PM

Sunday, October 09, 2011 8:14:28 PM

Post# of 253261
One of SNY's arguments against generic enoxaparin had been that it was impossible to characterize. While I cannot recall the exact date, there was a filing or letter with the FDA several years ago, perhaps by Ram, that mentioned that SNY admitted that they had only characterized about 76-80% of the drug (or thereabouts).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up